Adial Pharmaceuticals, Inc (ADIL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADIL Stock Price Chart Interactive Chart >
ADIL Price/Volume Stats
| Current price | $0.35 | 52-week high | $2.27 |
| Prev. close | $0.36 | 52-week low | $0.20 |
| Day low | $0.33 | Volume | 140,654 |
| Day high | $0.36 | Avg. volume | 738,148 |
| 50-day MA | $0.41 | Dividend yield | N/A |
| 200-day MA | $0.51 | Market Cap | 9.98M |
Adial Pharmaceuticals, Inc (ADIL) Company Bio
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Latest ADIL News From Around the Web
Below are the latest news stories about ADIAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ADIL as an investment opportunity.
Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use DisorderThe Keswick Group is led by experienced pharmaceutical business development executive, Tony GoodmanCHARLOTTESVILLE, Va., March 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it has engaged The Keswick Group, LLC, a biotech strategic commercial and business development advisory fi |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're getting into the biggest pre-market stock movers traders will want to keep an eye on Wednesday with the latest news! |
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14thCHARLOTTESVILLE, Va., March 08, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, President and Chief Executive Officer of Adial, will be presenting at the 35th Annual Roth Conference being held March 13 - 14, 2023 at The Ritz Carlton, Laguna Niguel located in Dana |
Adial Pharma Sees Clear, Cost-Effective Path Toward FDA Approval For Alcohol Use Disorder CandidateAdial Pharmaceuticals Inc (NASDAQ: ADIL) shares are trading higher after an update on its regulatory strategy for AD04, the company's lead compound for Alcohol Use Disorder (AUD). The company said additional analysis of ONWARD data identified specific genotypes that outperformed others. The data exhibited AD04 achieved a statistically significant reduction of heavy drinking days in a subgroup of patients - the "heavy drinkers." Adial believes there is a clear, cost-effective path toward FDA appr |
Meta’s stock up on report of more layoffs, and WeightWatchers telehealth deal gives it access to promising obesity drug marketADial Pharmaceuticals stock soars after alcohol disorder treatment clinical trial news, Squarespace rises after estimate-beating results. |
ADIL Price Returns
| 1-mo | -22.22% |
| 3-mo | 62.79% |
| 6-mo | 0.00% |
| 1-year | -82.59% |
| 3-year | -73.08% |
| 5-year | N/A |
| YTD | 62.79% |
| 2022 | -92.04% |
| 2021 | 58.82% |
| 2020 | -29.46% |
| 2019 | -52.93% |
| 2018 | N/A |
Loading social stream, please wait...